Prnewswire
Search documents
International Tower Hill Mines to Give Updated Presentation at BMO Global Metals, Mining & Critical Minerals Conference on February 25th and Extends Webcast Invitation
Prnewswire· 2026-02-23 13:30
International Tower Hill Mines to Give Updated Presentation at BMO Global Metals, Mining & Critical Minerals Conference on February 25th and Extends Webcast Invitation [Accessibility Statement] Skip NavigationVANCOUVER, BC, Feb. 23, 2026 /PRNewswire/ - International Tower Hill Mines Ltd. (the "Company", "ITH") - (TSX: ITH) (NYSE American: THM) today announced the Company will be presenting at BMO's 35th annual Global Metals, Mining & Critical Minerals Conference in Hollywood, Florida on February 25, 2026.Jo ...
Beacon Financial Corporation Announces Debut of Beacon Bank
Prnewswire· 2026-02-23 13:30
Beacon Financial Corporation Announces Debut of Beacon Bank [Accessibility Statement] Skip NavigationOne of 100 largest banks in the United StatesBOSTON, Feb. 23, 2026 /PRNewswire/ -- [Beacon Financial Corporation](NYSE: BBT) (the "Company") today announced the successful combination of four storied financial institutions under one new brand, [Beacon Bank](the "Bank"), one of the 100 largest banks in the United States.Continue ReadingBeacon Bank has more than 145 branches and commercial centers across New E ...
Marpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform Expansion
Prnewswire· 2026-02-23 13:08
Marpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform Expansion [Accessibility Statement] Skip NavigationNew Client Momentum Highlights Rapid Adoption of Marpai's Disruptive, Scalable Healthcare Platform Positioned to Drive Exponential Revenue Growth and Long-Term Shareholder ValueTAMPA, Fla., Feb. 23, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administ ...
QYOU is Now a Badged TikTok Agency Partner
Prnewswire· 2026-02-23 13:05
Core Insights - QYOU Media has been recognized as a TikTok Agency Partner, highlighting its expertise in creator marketing and ability to help brands succeed on the platform [1][1] - The partnership allows QYOU to assist brands in building and optimizing high-performing TikTok campaigns, leveraging its proven track record [1][1] - QYOU's approach integrates creator marketing with media, delivering a unified strategy based on TikTok's best practices [1][1] Company Achievements - QYOU has partnered with major organizations such as Paramount Pictures, Kraft Heinz, Disney, and Activision, showcasing its strong track record on TikTok [1][1] - The company has received multiple accolades for its campaigns, including awards from the Telly Awards, Webby Awards, Shorty Awards, and Digiday Content Marketing Awards [1][1] - Recent campaigns recognized include "Smile 2" and "A Quiet Place: Day One" from Paramount Pictures, and "Assassin's Creed Mirage" from Ubisoft, demonstrating QYOU's effectiveness in various categories [1][1] Strategic Developments - QYOU is formalizing and expanding its media practice to enhance the distribution and amplification of creator-led content on TikTok [1][1] - The company is investing in dedicated media expertise and scalable solutions that complement its creator-first foundation [1][1] - The partnership with TikTok positions QYOU to play a significant role in shaping modern creator marketing as brands increasingly turn to TikTok for engagement [1][1]
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Prnewswire· 2026-02-23 13:01
Core Viewpoint - Aethlon Medical, Inc. is set to present at the Emerging Growth Conference on February 25, 2026, highlighting its focus on developing medical products for cancer and life-threatening infectious diseases [1] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, specializing in the development of the Hemopurifier, which targets pathogenic substances in biological fluids [1] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, addressing unmet needs in oncology and infectious diseases [1] Product Details - The Hemopurifier has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard therapies and for addressing life-threatening viruses [1] - The device operates extracorporeally with a blood pump, utilizing plasma separation, size exclusion, and affinity binding to target mannose-rich surfaces on EVs and viruses [1] Conference Information - The Emerging Growth Conference provides a platform for public companies to present their innovations and engage with investors, featuring a live interactive format [1] - Aethlon's CEO and CFO will participate in a fireside chat and answer questions from attendees, with an archived webcast available for those unable to attend live [1]
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
Prnewswire· 2026-02-23 13:01
Core Viewpoint - TransCode Therapeutics has published a manuscript detailing a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells, enhancing drug delivery imaging capabilities [1]. Group 1: Research and Development - The published study in the journal Molecular Imaging and Biology describes a template-driven RIG-I agonist strategy that selectively activates RIG-I signaling in tumor cells by utilizing overexpressed oncogenic microRNAs, such as miRNA-21, as assembly templates [1]. - This new approach aims to address challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery [1]. - The findings suggest a method to engage innate immune pathways directly within tumor cells while minimizing systemic toxicity, potentially advancing RIG-I-based immunotherapy towards clinical relevance [1]. Group 2: Clinical Trials and Therapeutic Candidates - TransCode's TTX delivery platform, which is currently under evaluation in clinical trials, is expected to enhance the translational feasibility of this immunotherapy approach [1]. - The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis [1]. - TransCode's portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells [1].
KB HOME ANNOUNCES THE GRAND OPENING OF ITS THIRD NEW COMMUNITY WITHIN THE HIGHLY DESIRABLE COMPASS POINTE MASTER PLAN IN ONTARIO, CALIFORNIA
Prnewswire· 2026-02-23 13:00
Equinox at Compass Pointe offers personalized new townhomes with planned community amenities and walking distance to top-rated schools and parks, priced from the low $500,000s. ONTARIO, Calif., Feb. 23, 2026 /PRNewswire/ -- KB Home (NYSE: KBH), one of the largest and most trusted homebuilders in the U.S., today announced the grand opening of Equinox, its newest community within the highly desirable Compass Pointe master plan in Ontario, California. Situated in San Bernardino County, Ontario is an ideal blen ...
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Prnewswire· 2026-02-23 13:00
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCsâ"¢") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special M ...
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Prnewswire· 2026-02-23 13:00
Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should re ...
CONTANGO ORE, INC. ANNOUNCES FILING AND MAILING OF SPECIAL MEETING PROXY STATEMENT IN CONNECTION WITH THE PROPOSED PLAN OF ARRANGEMENT WITH DOLLY VARDEN
Prnewswire· 2026-02-23 13:00
that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the projections in the forward-looking statements. Forward-looking statements are based on the estimates and opinions of management at the time the statements are made. Contango does not assume any obligation to update forward-looking statements should circumstances or management's estimates or opinions change.SOURCE Contango Ore## 21%[more press release views with Reque ...